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FerraraAbstract—In the last decade, ultrasound deformation imaging, based on both Doppler and speckle tracking
echocardiography techniques, has emerged as a more sensitive tool to identify subtle and subclinical left ventric-
ular systolic dysfunction in several clinical settings compared with ejection fraction. In this article, we review
the evidence relative to the application of ultrasound deformation imaging to the oncologic field for detection
of left ventricular systolic dysfunction induced by cardiotoxic treatments with the aim of verifying whether this
approach may actually help in early diagnosis of chemotherapy-induced cardiotoxicity. (E-mail: donatomele@
libero.it)  2015 World Federation for Ultrasound in Medicine & Biology.
Key Words: Speckle tracking echocardiography, Cardiotoxicity, Chemotherapy, Trastuzumab, Anthracyclines.INTRODUCTION
Modern oncologic treatments have led to a reduction in
the mortality rate among patients with cancer (Coleman
et al. 2011). However, some anti-neoplastic therapies
may also have toxic effects on the heart and lead to the
development of a number of cardiovascular complications
(such as heart failure, myocardial ischemia, hypertension,
thromboembolism and arrhythmias), which may have sig-
nificant consequences on patient outcomes. For example,
a survival rate of about 50% at 2 y has been reported for
patients who develop heart failure and cardiomyopathy
from anthracycline treatment (Felker et al. 2000). This
subject has forced both cardiologists and oncologists to
deal with the early detection of cardiotoxicity to set up
strategies to prevent irreversible cardiac damage and heart
failure (Jurcut et al. 2008b;Monsuez 2012; Schwartz et al.
2013; Wu 2008).
Cancer therapy-induced cardiotoxicity may vary in
terms of mechanisms, pathophysiology, presentation and
prevalence depending on several factors, including the
types of drugs used (e.g., anthracyclines, trastuzumab,
cyclophosphamide) (Yeh and Bickford 2009). Anthracy-
clines, such as doxorubicin and epirubicin, which are
employed in both solid and hematologic malignancies,ddress correspondence to: DonatoMele, Department of Cardiol-
zienda Ospedaliero-Universitaria, Via Aldo Moro 8, 44124 Cona,
, Italy. E-mail: donatomele@libero.it
627directly damage the myocardium mainly through produc-
tion of oxygen free radicals, leading to left ventricular
(LV) systolic dysfunction and, in some cases, an irrevers-
ible cardiomyopathy. This toxicity is cumulative and
dose dependent. A 3%–26% incidence of LV systolic
dysfunction has been associated with doxorubicin utiliza-
tion (Yeh andBickford 2009). Trastuzumab is a humanized
monoclonal antibody against the extracellular domain of
the human epidermal growth factor receptor 2 (HER2)
and is part of the standard treatment for breast cancer
with HER2 overexpression and/or amplification. The
incidence of LV systolic dysfunction ranges from 2%
to 7% when trastuzumab is used as monotherapy and
may be as high as 27% when it is used concurrently with
anthracyclines plus cyclophosphamide (Yeh and Bickford
2009). Many other anti-cancer drugs may determine
cardiotoxicity, with variable incidence rates, and dedicated
reviews can be consulted for specific information in this
regard (Curigliano et al. 2010; Yeh and Bickford 2009).
Cardiotoxicity is generally evaluated assessing the
LV ejection fraction (LV-EF), which is defined as the
LV (end-diastolic volume minus the end-systolic vol-
ume)/end-diastolic volume. Generally, the LV-EF is
obtained using 2-D echocardiography, which has the
advantage of being a widespread technique. On the
basis of the Cardiac Review and Evaluation Committee
of Trastuzumab-Associated Cardiotoxicity (CREC)
(Seidman et al. 2002), cardiotoxicity is defined as a
reduction in LV-EF of $5% to ,55% with symptoms
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$10% to ,55%. According to the European Society for
Medical Oncology (ESMO) Clinical Practice Guidelines
(Bovelli et al. 2010), in patients undergoing anti-cancer
therapy with anthracyclines and their derivates or mono-
clonal antibodies, a reduction in LV-EF of $20% from
baseline despite normal function or a LV-EF ,50%
necessitates re-assessment or discontinuation of therapy
and further frequent clinical and echocardiographic
checks.
A reduction in LV-EF of less than 10%–20% from
baseline in asymptomatic patients, as suggested by the
ESMO and CREC recommendations, is not sensitive
enough to reveal subclinical or regional myocardial
dysfunction when 2-D echocardiography is used for
calculation (Manisty and Francis 2008; Mele 2011;
Thavendiranathan et al. 2013). To improve accuracy and
reproducibility, 3-D echocardiography was introduced
for evaluation of LV-EF. In patients undergoing cancer
chemotherapy, it has been found that non-contrast 3-D
LV-EF has better intra-observer, inter-observer and
test–retest variability than 2-D echocardiography
(Thavendiranathan et al. 2013). However, even 3-D
LV-EF can be less sensitive for recognition of subtle LV
systolic dysfunction compared with other imaging
techniques assessing LV myocardial rather than cardiac
pump function (Hare et al. 2009). Therefore, the use of
LV-EF, despite its high feasibility when calculated by
2-D echocardiography, and the increased accuracy and
reproducibility of measurements when obtained by the
3-D echocardiography approach, may be still questionable
for early detection of cardiotoxicity, mainly because of its
intrinsic limitations (Manisty and Francis 2008).
In recent years, ultrasound deformation imaging,
obtained by both Doppler and speckle tracking echocar-
diography (STE) techniques, has been proposed for
detection of myocardial dysfunction as an alternative to
LV-EF (Mondillo et al. 2011; Yip et al. 2011). This
approach has emerged as a more sensitive tool with
which to identify subtle and subclinical LV systolic
dysfunction in several clinical settings (Biswas et al.
2013), including assessment of anti-neoplastic treatments
(Stoodley et al. 2011b; Thavendiranathan et al. 2014). In
this article, we review the evidence on application of ul-
trasound deformation imaging in the oncologic field to
verify whether it may actually help in the early diagnosis
of chemotherapy-induced cardiotoxicity.Fig. 1. Schematic of the left ventricle (LV) with the three
main directions of the myocardial deformation: longitudinal,
circumferential and radial. Thick arrows indicate the opposing
rotational motion of the left ventricular base and apex, gener-
ating a twisting movement of the whole LV.ULTRASOUND DEFORMATION IMAGING
Left ventricular contraction is complex and gener-
ates multiple myocardial deformations in different spatial
directions. In brief, during the ejection phase of systole,
the LV myocardium shortens in the longitudinal andcircumferential directions and thickens in the radial
direction (Fig. 1). In a normal contracting LV, these
regional myocardial deformations occur synchronously.
Also, normally the LV base and apex rotate in opposite
directions during ventricular ejection (clockwise for the
base and counterclockwise for the apex), thus generating
torsional motion of the whole LV (Fig. 1). This is due to
the characteristic helical architecture of the LV myocar-
dium (Buckberg 2002). A reduction in systolic twisting
and twisting velocity (and/or diastolic untwisting and
untwisting velocity) indicates LV systolic dysfunction
(and/or diastolic dysfunction). Reversed apical rotation
as a marker of disease severity has been described
in dilated cardiomyopathy (Popescu et al. 2009).
Longitudinal, circumferential and radial deforma-
tions are generally expressed in terms of strain, that is,
the percentage of deformation, which is positive if the
deformation is elongation or negative if the deformation
is shortening. Strain rate is the rate at which strain changes
and is expressed per second (or in hertz, i.e., the change in
strain per unit time). Normally, LV longitudinal and
circumferential strain and strain rate are negative, whereas
radial strain and strain rate are positive. Basal and apical
LV rotation is expressed in degrees, as is twisting, which
is their algebraic sum; torsion is obtained by dividing
twisting by the length of the LV cavity in degrees per
centimeter. Systolic rotation and twisting velocity can
also be measured in degrees per second (Cheung et al.
2011; Motoki et al. 2012).
Myocardial deformations can be studied non-
invasively by magnetic resonance imaging (MRI) using
Echocardiography and cardiotoxicity d D. MELE et al. 629the tagging technique, as well as by ultrasound deforma-
tion imaging, which includes the Doppler strain imaging
(DSI) technique, 2-D- and 3-D-STE and velocity vector
imaging (VVI).
The DSI technique is based on color Doppler tissue
imaging, a method that uses Doppler interrogation of
myocardial tissue moving during the cardiac cycle to
measure myocardial velocities (Hoit 2011; Mor-Avi
et al. 2011). From these velocities, the myocardial
strain rate and strain are then mathematically
calculated. In particular, the strain rate corresponds to
the spatial gradient of tissue velocity and can therefore
be obtained from the color Doppler data as the
difference between velocities measured in two samples
1 and 2, divided by the distance r between the two
samples: strain rate 5 (V22V1)/r. Strain is calculated as
the temporal integral of strain rate. The strain rate and
strain data relative to the myocardial deformation can
be illustrated using both a color-coded 2-D image
representation and tissue curves that are generated from
the color Doppler data (Fig. 2). The DSI technique has
been validated against both sonomicrometry (Urheim
et al. 2000) and MRI (Edvardsen et al. 2002).
The 2-D STE technique evaluates myocardial
deformation through analysis of gray-scale conventional
echocardiographic B-mode images (Hoit 2011; Mor-Avi
et al. 2011). With this technology, the speckles seen inFig. 2. Doppler strain imaging. Left: Echocardiographic end-sy
Doppler myocardial strain rate (top) and strain (bottom) inform
longitudinal strain rate (top) and strain (bottom) traces from the
peak systolic strain rate and strain. AVC 5 aorticthe gray-scale B-mode images can be tracked from frame
to frame and simultaneously in multiple regions within an
image plane. By use of this analysis, information on local
displacement of speckles is obtained, from which strain
rate, strain, rotation and torsion parameters can be
derived. As for DSI, representation of myocardial defor-
mation by STE is performed using both color-coded
images and curves (Figs. 3–5). The 2-D STE technique
has been validated with both sonomicrometry and MRI
(Amundsen et al. 2006; Helle-Valle et al. 2005), and its
reliability in patients treated with anthracyclines has
also been specifically evaluated (Mavinkurve-Groothuis
et al. 2009).
The 3-D-STE technique is based on acquisition of a
volume of echocardiographic data, generally from the
apical window. The processing of 3-D-STE is generally
similar to that of 2-D STE (Biswas et al. 2013). Unlike
2-D-STE, a combined assessment of longitudinal and
circumferential strain can be performed by 3-D-STE,
and this is termed area strain (Miyoshi et al. 2014)
(Fig. 6). As the values of both longitudinal and circumfer-
ential strains are negative in a normal subject, area strain
will also be negative. The 3-D-STE technique has been
validated against sonomicrometry (Seo et al. 2009), but
current guidelines, at present, do not suggest routine
use of this approach for clinical applications (Jasaityte
et al. 2013; Mor-Avi et al. 2011).stolic images of the left ventricle with superimposed color
ation and marked sample volume position. Right: Typical
myocardial region indicated on the left. Arrows indicate
valve closure; AVO 5 aortic valve opening.
Fig. 3. Analysis of myocardial strain of the left ventricle based on 2-D speckle tracking echocardiography. Left: The
region of interest for circumferential and radial strain calculation (in color) is overimposed on the left ventricular
myocardium of a short-axis view taken at the mid-ventricular level. Middle: The left ventricular myocardium is
divided into six segments. For each myocardial segment, the average strain value is indicated. Right: For both
circumferential and radial strain, the six strain curves relative to the corresponding left ventricular myocardial
segments are shown. The white dotted curve represents the average of the six curves for circumferential strain.
The time of aortic valve closure (AVC) is indicated.
Fig. 4. Typical mean rotation and rotation rate curves of the left ventricular apex (left) and base (right) obtained by 2-D
speckle tracking echocardiography. The directions of systolic rotation and rotation rate are opposite at the apical and basal
levels. The left ventricle short-axis color-coded images are taken at end-systole (top) and at peak systolic rotation rate
(bottom), as indicated by the yellow arrows. AVC 5 aortic valve closure.
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Fig. 5. Two-dimensional speckle tracking echocardiography short-axis view of the left ventricle taken at the apical
and basal levels, illustrating clockwise basal rotation and counterclockwise apical rotation in a normal subject.
The combination of basal and apical rotation in opposite directions results in left ventricular twisting. AVC 5 aortic
valve closure.
Echocardiography and cardiotoxicity d D. MELE et al. 631The VVI technique is an advanced echocardio-
graphic method that is based on STE (Bansal et al.
2008; Mor-Avi et al. 2011). It automatically calculates
instantaneous velocity vectors of the myocardium with
different directions and sizes. These vectors are
superimposed on the dynamic B-mode images (Fig. 7).Fig. 6. Left: Example of left ventricular Images generated from
four-chamber view. (B) two-chamber view. (C) long-axis view. (
and basal (F) levels. The epicardial and endocardial borders are
tudinal, circumferential and radial directions. Middle: The com
is termed area strain (A), as illustrated schematically on the
ventricle segment, area strain values are represented as curves (t
The global area strain is calculated as the average of alAnalysis of myocardial deformation is today
possible using all the mainstream commercially available
ultrasound systems. However, to reduce inter-vendor vari-
ability in strain measurement, at present it is reasonable to
use the same vendor’s machine to compare individual
patients when using 2-D STE for the serial evaluation ofa pyramidal 3-D echocardiographic data set: (A) Apical
D–F) short-axis views at the apical (D), mid-ventricle (E)
traced to calculate myocardial deformation in the longi-
bination of longitudinal (L) and circumferential (C) strain
reconstructed left ventricle model. Right: For each left
op) and numbers in the bull’s eye representation (bottom).
l the segmental values (thick white dotted curve).
Fig. 7. Velocity vector imaging applied to a short-axis view of the left ventricle. With this technique, the endocardial
border of the left ventricle is tracked throughout the cardiac cycle, and the tissue velocity is indicated by vectors (arrows).
At end-systole, motion is directed inward; the opposite occurs at early diastole. The amplitude of the arrows is propor-
tional to the velocity.
632 Ultrasound in Medicine and Biology Volume 41, Number 3, 2015LV systolic function. Undoubtedly, the wide availability
of echo scanners equipped with 2-D STE can facilitate
the extensive application of deformation analysis in
clinical practice, which cannot be performed systemati-
cally with the tagging MRI technique. Tagging MRI, in
fact, is not performed in everyMRI laboratory on a routine
basis; also, access to cardiac MRI is limited in most
centers, and the technique is expensive and not tolerated
by claustrophobic patients.
In cardio-oncology, analysis of myocardial deforma-
tion has so far been based mainly on application of ultra-
sound techniques. In general, the maximal extent of
systolic myocardial deformation (peak systolic strain)
and its peak rate (peak systolic strain rate) have been
used, both regionally and globally, for cardiotoxicity
assessment. In particular, a parameter called systolic
global longitudinal strain (GLS) has gained increasing
interest. The GLS is calculated as the mean of the peak
systolic strain values of 18 cardiac segments obtained
from the three standard apical four-chamber, two-cham-
ber and long-axis views (Fig. 8). Results are generally
presented as a bull-eye plot with all individual segmental
values, mean value of each standard view and GLS
(Fig. 9). For breast cancer patients, some authors
calculated GLS as the mean of eight segments, namely,
the basal and mid-ventricular segments of the four- and
two-chamber views (Sawaya et al. 2011, 2012): in these
patients the apical segments were excluded because of
difficulty in visualizing the apex, mainly because of
breast surgery, postsurgical changes and the presence
of expanders or breast implants. Global radial and
circumferential strain (GRS, GCS) can also becalculated by averaging peak systolic radial and
circumferential strain obtained at a regional level in the
short-axis views. Generally, a single mid-ventricle
(papillary level) short-axis view is used to this purpose.
Diastolic strain and strain rate parameters (global
longitudinal peak systolic strain rate [GLSR-S], global
longitudinal early diastolic strain rate [GLSR-E]) have
also been used, although less frequently (Negishi et al.
2013), as has diastolic untwisting and untwisting velocity
(Cheung et al. 2011; Motoki et al. 2012).DOPPLER STRAIN IMAGING
Experimental studies in mice and rats treated with
chemotherapy have indicated that myocardial deforma-
tion indices obtained with this technique can detect early
LV dysfunction before alterations in conventional
echocardiographic indices and Doppler tissue imaging
velocities and can predict early mortality (Jassal et al.
2009; Neilan et al. 2006; Piegari et al. 2008).
In patients, some authors have reported that the
septal longitudinal myocardial deformation decreases
after a low cumulative dose of epirubicin (,200 mg/m2
body surface area) (Mercuro et al. 2007) and that this
reduction persists up to 18 mo of follow-up despite
cessation of therapy (Mantovani et al. 2008). These
observations suggest that myocardial deformation
analysis can recognize early epirubicin cardiotoxicity
that can occur at a dose of 200 mg/m2, generally consid-
ered very low by oncologists, that is, not able to induce
significant toxicity (Ryberg et al. 1998). The reduction
in peak strain rate also preceded signs of diastolic
Fig. 8. Analysis of myocardial longitudinal strain of the left ventricle based on 2-D speckle tracking echocardiography.
Left: The region of interest for longitudinal strain calculation (in color) is superimposed on the left ventricular
myocardium of the three standard apical views (four-chamber [4-Ch], two-chamber [2-Ch] and long-axis [LAX] views
from top to bottom). Middle: In each view the left ventricular myocardium is divided into six segments. The average value
of longitudinal strain for each myocardial segment is reported. Right: In each panel, from top to bottom, are the six
longitudinal strain curves corresponding to the left ventricular myocardial segments. The white dotted curve represents
the average of the six curves of each panel, and its peak systolic value is taken for calculation of the global longitudinal
strain. AVC 5 aortic valve closure.
Echocardiography and cardiotoxicity d D. MELE et al. 633dysfunction, which occurred at higher doses of epirubicin
(300 mg/m2). This observation is of particular interest
because it indicates that systolic dysfunction may occur
before or without a diastolic impairment if appropriate
parameters are used for its assessment (Jurcut et al.
2008a). It is also noteworthy that DSI can detect subtle
worsening in longitudinal and radial LV systolic function
even when new anthracycline formulations (e.g., pegy-
lated liposomal doxorubicin) are used (Jurcut et al.
2008a; Wildiers et al. 2008): in the two studies that
evaluated these formulations, changes in radial function
appeared earlier and were more pronounced than
changes in longitudinal direction (Jurcut et al. 2008a;
Wildiers et al. 2008).
Ganame et al. (2007a), in a pediatric study popula-
tion, found that both longitudinal and radial myocardial
strain and strain rate decreased significantly after the first
dose of chemotherapy; after the third dose, however,
although longitudinal strain did not decrease, radial
deformation continued to decrease, indicating further
deterioration of myocardial function, but also a difference
in the behavior of deformation parameters. Subsequent
studies have confirmed the value of DSI in recognizingthe early functional impairment caused by anthracyclines
(Ganame et al. 2007b) and trastuzumab (Hare et al.
2009).
The study of Hare et al. (2009) in patients with
breast cancer undergoing therapy with trastuzumab is of
particular interest because LV-EF was measured by
both 2-D and 3-D echocardiography. In this investigation,
the use of 3-D echocardiography as a more sensitive and
reproducible measure of LV-EF was not reliable enough
to detect changes in LV function caused by the anti-
cancer treatment. On the contrary, longitudinal systolic
strain rate, as a sensitive marker of myocardial function,
significantly decreased over time during follow-up after
trastuzumab commencement.
Using DSI, Erven et al. (2011) studied the occur-
rence of early radiation-induced changes in regional
cardiac function. These authors included left-sided and
right-sided breast cancer patients receiving radiotherapy
to the breast or chest wall. The ultrasound evaluation
was performed before, immediately after and 2 mo after
radiotherapy. A reduction in regional systolic strain was
observed immediately post-radiotherapy and at the
follow-up evaluation in patients with left-sided but not
Fig. 9. Average peak systolic longitudinal strain values of each left ventricular myocardial segment are reported in a bull’s
eye plot for a normal subject (left) and a patient with chemotherapy-induced cardiotoxicity (right). As illustrated on the
colored strain bars, segments with normal strain values are depicted in dark red, whereas other colors indicate progressive
degrees of systolic dysfunction. A clear septal systolic abnormality is recognizable in the patient with cardiotoxicity.
A4 C 5 apical four-chamber; A2C 5 apical two-chamber; Avg 5 average; GLPS 5 global longitudinal peak strain;
LAX 5 long-axis.
634 Ultrasound in Medicine and Biology Volume 41, Number 3, 2015right–sided breast cancer. Within the left-sided patient
group, systolic strain and strain rate were significantly
reduced after radiotherapy in the apical LV segments,
but not in mid- or basal segments. Furthermore, segments
exposed to more than 3 Gy had a significant decrease in
systolic strain after radiotherapy, but this was not
observed in segments receiving less than 3 Gy, indicating
a dose-related regional decrease in myocardial function
after radiotherapy. In a subsequent study (Erven et al.
2013), the same authors observed that in contrast to
conventional echocardiography, DSI could detect a
regional, subclinical decline in cardiac function up to
14 mo after breast radiotherapy.
There have been some studies on the role of DSI
for assessment of cardioprotection strategies. Cadeddu
et al. (2010) studied 49 patients affected by a variety
of solid cancers, selected at random to receive telm-
isartan, an angiotensin II type 1 receptor blocker, or pla-
cebo, starting 1 wk before chemotherapy. Evaluations
were performed at baseline and 7 d after every new
epirubicin dose of 100 mg/m2. Impairment of peak
systolic strain rate was reported at an epirubicin dose
of 200 mg/m2, with no significant differences between
telmisartan and placebo (1.41 6 0.31 vs. 1.59 6 0.36/
s). At growing cumulative doses of epirubicin, strain
rate normalized in telmisartan-treated patients, resulting
in a significant difference in comparison to placebo
at epirubicin doses of 300 mg/m2 (1.69 6 0.42/s vs.1.34 6 0.18/s, p , 0.001) and 400 mg/m2 (1.74 6
0.27/s vs. 1.38 6 0.24/s, p , 0.001). In a subsequent
study (Dessı et al. 2011), the same authors observed
that telmisartan not only reverses acute (early)
epirubicin-induced LV myocardial systolic dysfunction,
but also helps maintain normal systolic function up to a
follow-up period of 12 mo.
Zhang et al. (2012), in 60 patients with breast cancer,
evaluated the cardioprotective effects of salidroside on
epirubicin-induced cardiotoxicity using a protocol
similar to that of Cadeddu et al. (2010). A decline in
peak systolic strain rate was observed at an epirubicin
dose of 200 mg/m2, with no significant differences
between salidroside and placebo (1.35 6 0.36/s vs. 1.42
6 0.49/s). At growing cumulative doses of epirubicin,
peak strain rate values normalized only with salidroside,
resulting in a significant difference in comparison with
placebo at epirubicin doses of 300 mg/m2 (1.67 6 0.43/
s vs. 1.32 6 0.53/s, p , 0.05) and 400 mg/m2 (1.68 6
0.29/s vs 1.40 6 0.23/s, p , 0.05).Summary
From the studies reported above, it appears that the
DSI technique: is more sensitive than LV-EF assessment,
even by 3-D echocardiography, in recognizing LV sys-
tolic dysfunction caused by anti-cancer treatments,
including chemo- and radiotherapy; can identify early
Echocardiography and cardiotoxicity d D. MELE et al. 635cardiotoxicity, even at low doses of anthracyclines and
before or in the absence of diastolic dysfunction; and
can reveal differences inmyocardial function at a regional
level, identifying those segments that are more affected
by the cardiotoxic hit (generally, inter-ventricular septum
longitudinal deformation seems to be most consistently
impaired during anti-cancer treatments).
Most of the published databases on DSI have used
longitudinal peak systolic strain rate rather than peak
systolic strain for evaluation of myocardial systolic
function. Only some investigations have also assessed
radial strain, which has been reported by some authors
to change earlier and to a greater degree than longitudi-
nal deformation (Jurcut et al. 2008a; Wildiers et al.
2008).
Intra- and inter-observer variability for strain and
strain rate measurements by DSI is summarized in
Table 1.
Unfortunately, DSI has significant limitations for
extensive clinical use, including its limited reproduc-
ibility and generation of noisy curves (especially
with strain rate imaging), which may require expertise
for appropriate interpretation; also, the insonation
angle is crucial because results become unreliable
when the ultrasound beam direction is not parallel to
the direction of the myocardial wall deformation.
Additionally, DSI requires data acquisition for each
myocardial segment with careful attention to frame
rates, which limits the feasibility of the method.
Therefore, we believe that the DSI technique should
currently be considered as a second choice for assess-
ment of LV myocardial deformation in clinical prac-
tice when STE cannot be applied.Table 1. Intra- and inter-observer variability of strain and
Reference Number of patients Age (y) Cancer
Ganame et al. 2007a 13 10.7 6 3.8* Various Abso
LS: 2
LSR:
RS: 2
RSR:
Ganame et al. 2007b 56 4 6 28 Various Abso
LS: 2
LSR:
RS: 2
RSR:
Jurcut et al. 2008a 16 69.8 6 3.1 Breast Relat
Strain
Strain
Hare et al. 2009 35 51 6 8 Breast Mean
LS: 2
LSR:
CI 5 confidence interval; LS 5 longitudinal strain; LSR 5 longitudinal st
deviation.
* Mean 6 SD.
y Unspecified whether longitudinal or radial.TWO-DIMENSIONAL SPECKLE TRACKING
ECHOCARDIOGRAPHY
In an initial experimental study, 2-D STEwas able to
recognize the early damage caused by anthracyclines
(Migrino et al. 2008). Subsequently, this technique was
applied by many authors in clinical investigations with
favorable results. Studies can be grouped according to
the four main features addressed: (i) identification of
cardiotoxicity in patients previously treated with onco-
logic therapies; (ii) serial evaluations for prospective
early recognition of cardiotoxicity; (iii) prediction of
late cardiotoxicity development; and (iv) evaluation of
cardioprotection strategies.Identification of cardiotoxicity in previously treated
patients
Cheung et al. (2010) evaluated children with acute
lymphoblastic leukemia who had been off treatment for
at least 1 y and who had a LV shortening fraction within
normal limits (.28%). In comparison to a group of 44
control patients, the study group exhibited impaired LV
myocardial deformation in terms of GLS, GRS and
GCS, that is, in all of the three main directions of defor-
mation. In another study (Cheung et al. 2011), the same
authors examined a smaller group of children with the
same pathology who also had been off anthracycline
treatment for at least 1 y and found that, compared with
a control group, they had reduced peak LV torsion,
systolic twisting velocity and diastolic untwisting veloc-
ity, which could be attributable to their reduced apical
rotation and apical untwisting rate. Twenty-eight (78%)
patients had LV-EFs$50%. In a third recent investigationstrain rate measurements by Doppler strain imaging
Intra-observer variability Inter-observer variability
lute mean difference (95% CI):
.67% (3.69%)
0.13/s (0.13/s)
.03% (2.81%)
0.44/s (0.36/s)
Absolute mean difference (95% CI):
LS: 5.14% (3.73%)
LSR: 0.44/s (0.41/s)
RS: 6.44% (8.96%)
RSR: 0.50/s (0.43/s)
lute mean difference (95% CI):
.56% (3.72%)
0.11/s (0.12/s)
.79% (2.91%)
0.51/s (0.47/s)
Absolute mean difference (95% CI):
LS: 3.48% (3.89%)
LSR: 0.41/s (0.42/s)
RS: 6.03% (8.57%)
RSR: 0.53/s (0.59/s)
ive mean difference:
: 8.3%y
rate: 9.1%y
No data
difference 6 SD (95% CI):
0.3 6 1.3% (62.5%)
20.03 6 0.11/s (60.21/s)
Mean difference 6 SD (95% CI):
LS: 20.03 6 0.11% (60.21%)
LSR: 0.00 6 0.18/s (60.36/s)
rain rate; RS 5 radial strain; RSR 5 radial strain rate; SD 5 standard
636 Ultrasound in Medicine and Biology Volume 41, Number 3, 2015on 32 anthracycline-treated survivors of childhoodmalig-
nancies (Yu et al. 2013b), these authors reported that the
apical rotation, systolic twisting velocity and diastolic
untwisting velocity were reduced preferentially at the
subendocardial layer, hence accounting for their signifi-
cantly reduced transmural rotation gradient compared
with controls.
Yagci-Kupeli et al. (2012) studied a group of 19
pediatric cancer patients treated with high-dose anthracy-
clines and a control group. Therewas no significant differ-
ence in LV-EF between the two groups. Peak systolic
strain and strain rates of the right ventricle and of the basal
regions of the left ventricle (septal, lateral and inferior
walls) were significantly lower in patients than controls.
Ho et al. (2010) found that despite a normal LV-EF,
2-D STE can detect subclinical systolic myocardial
abnormalities in asymptomatic breast cancer survivors
who had received anthracycline treatment with or without
adjuvant trastuzumab up to 6 y previously. In particular,
just over one-quarter (26%) of the chemotherapy group
had GLS values below the lower limits of a normal con-
trol group. Interestingly, cigarette smoking was an
independent predictor of longitudinal strain in the chemo-
therapy group.
Bi et al. (2009) studied a total of 116 breast cancer
patients treated with epirubicin who were divided into
three groups: 28 were given epirubicin 120–340 mg/m2
(group A), 42 received epirubicin $360 mg/m2
(group B), and 36 received no chemotherapy (control
group). There was no significant change in conventional
echocardiographic parameters among the three groups,
whereas peak systolic strain of LV subendocardial
myocardium in groups A and B was reduced in some seg-
ments compared with the controls.
Khouri et al. (2014) studied 57 asymptomatic
women with early breast cancer (mean: 26 6 22 mo
post-chemotherapy) and 20 sex-matched controls with
an integrated approach using 3-D echocardiography,
GLS by 2-D STE and exercise stress echocardiography
for detecting subclinical cardiac dysfunction. After
resting assessments, patients completed cardiopulmonary
exercise testing with stress 2-D echocardiography.
Resting LV-EF was lower in patients than controls by
3-D but not 2-D echocardiography. A subgroup of 10
patients had a mean 20% impairment in GLS (216.1 6
0.9% vs. 220.1 6 1.5%, p , 0.001) despite similar
LV-EF by 2-D and 3-D echocardiography compared
with controls. Cardiopulmonary function (VO2 peak)
was 20% lower in patients than controls, and post-
exercise increase in cardiac index predicted VO2 peak.
Tsai et al. (2011) applied 2-D STE to long-term sur-
vivors of Hodgkin’s lymphoma 226 2 y after successful
mediastinal radiotherapy. Patients were divided into two
groups according to previous lymphoma treatment eitherwith or without anthracyclines. The patients who had
received anthracycline and mediastinal radiotherapy
had a significantly reduced GLS compared with those
who had undergone radiotherapy alone or radiotherapy
combined with regimens without anthracycline. LV-EF
did not differ between the two patient groups. The GCS
was also similar in the two groups of patients.
Gziri et al. (2013), in a controlled study, evaluated 62
children exposed to chemotherapyduring fetal life andpro-
vided interesting insights into the effect on cardiac function
after in utero exposure to maternal chemotherapy. LV sys-
tolic GLS and GCS were assessed. A small but significant
difference in LV-EF was observed (66% [57%–79%] in
patients vs. 70% [57%–83%] in controls, p , 0.001], but
no significant differences in LV systolic GLS and GCS
derived using 2-DSTEwere detected. On the basis of these
data, maternal chemotherapy does not seem to result in
cardiomyopathy or cardiac dysfunction during early
childhood. However, long-term follow-up data are
required to rule out an effect later in life.
Serial evaluations for prospective early recognition of
cardiotoxicity
Other investigators provided information on serial
evaluation of cardiac function, before and after oncologic
treatments, comparing 2-D STE with LV-EF evaluation.
Kang et al. (2013) detected subclinical myocardial injury
using 2-D STE immediately after epirubicin exposure
(i.e., 1 d after completion of therapy) in asymptomatic
patients with large B-cell non-Hodgkin lymphoma. In
particular, in 67 patients, despite normal LV-EF, a marked
reduction in GLS (16.18% 6 1.92% vs. 218.30% 6
1.87%, p , 0.01), GCS (218.25 6 2.40% vs. 220.37
6 2.89%, p , 0.01) and GRS (36.15 6 5.79% vs.
39.95 6 5.79%, p , 0.01) was observed in comparison
with baseline values.
Al-Biltagi et al. (2012) studied 25 children with
newly diagnosed acute lymphoblastic leukemia and 30
healthy control children before andwithin 1wk after doxo-
rubicin treatment using conventional echocardiography
and 2-D STE. These authors observed a reduction in
both LV shortening fraction by conventional echocardiog-
raphy (from 40.006 4.87 to 33.506 6.58%) and GLS by
2-D STE (from218.656 4.52% to215.106 2.45%, p,
0.01). Shortening fraction values, however, remained with
the normal limits.
Stoodley et al. (2011a), in women with breast
cancer, measured LV-EF, GLS, GRS and GCS by 2-D
STE 1wk before and 1wk after chemotherapy. After treat-
ment,GLSdecreased from217.7% to216.3% (p, 0.01)
with 48% of measurements reduced by .10%, and GRS
dropped from 40.5% to 34.5% (p , 0.01) with 59% of
measurements reduced by .10%. In contrast, there was
no reduction in LV-EF .10% after chemotherapy as
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strain rate. In another study performed on the same pa-
tients and with the same authors (Stoodley et al. 2013a),
altered LV diastolic function was also observed shortly
after anthracycline treatment. Measurements included
longitudinal diastolic strain as well as early and late
myocardial strain rate. Interestingly, changes in diastolic
function were associated with reduced systolic function
and especially with systolic strain reduction. In a third
study Stoodley et al. (2013b) evaluated 50 HER2/neu-
negative breast cancer patients over 12 mo with serial
echocardiograms at four time points. All patients were
treated with standard regimens containing anthracyclines.
Systolic GLS was significantly reduced immediately after
(1 wk) and 6mo after anthracyclines (from219.06 2.3%
to217.56 2.3%, p, 0.001, and to218.26 2.2%, p5
0.01, respectively). A non-uniform reduction in strain was
observed each time with relative sparing of the LV apex.
LV-EF remained largely unchanged at both time points.
Systolic GLS normalized by 12 mo in the majority of
patients (219.16 1.9% on average). Persistently reduced
strain was observed in 16% (n 5 8) of the study popula-
tion; these patients, who also achieved greater reductions
in strain at 6 mo (#217.2%), had received higher cumu-
lative anthracycline doses.
Fallah-Rad et al. (2011) reported that 2-D STE was
able to detect pre-clinical changes in LV systolic function
before changes in conventional LV-EF, in patients
receiving trastuzumab in the adjuvant setting. In patients
who developed trastuzumab-mediated cardiotoxicity ac-
cording to a LV-EF decline of at least 10% below 55%,
GLS and GRS decreased as early as 3 mo (from 219.8
6 1.8% to 216.4 6 1.1% for GLS; from 41.4 6 10.5%
to 34.5 6 15.2% for GRS), whereas the decrease in
LV-EF became significant only after 6 mo. A GLS cutoff
value of 2% and a GRS cutoff value of 0.80% (differences
between baseline and 3-mo values) had negative predic-
tive values for cardiotoxicity recognition of 92% and
95%, respectively. Interestingly, troponin T, C-reactive
protein and brain natriuretic peptide did not change
over time up to 1 y, whereas GLS, GRS and EF continued
to decline up to 9 mo.
Poterucha et al. (2012), in pediatric cancer patients
exposed to anthracycline chemotherapy, reported the
usefulness of 2-D STE in serial clinical monitoring of
cardiotoxicity. Echocardiography was performed at base-
line, mid-treatment and end-of-treatment points (0, 4 and
8 mo). There was a significant decrease in GLS compared
with baseline at 4 and 8 mo, whereas LV-EF exhibited a
statistically significant decrease only at 8 mo. Segmental
changes in mid- and apical LV longitudinal systolic strain
were significantly correlated with change in LV-EF, sug-
gesting an increased likelihood that depressed LV-EF will
be observed later in follow-up.Mavinkurve-Groothuis et al. (2013) studied 60
children with newly diagnosed acute lymphoblastic
leukemia before starting treatment with anthracyclines,
after 3 mo and after 1 y with measurements of cardiac
troponin T, N-terminal prohormone of brain natriuretic
peptide (NT-pro-BNP), conventional echocardiography
and 2-D STE. Cardiac function decreased significantly
during treatment. Also, at 3 mo, troponin T and NT-
pro-BNP levels were abnormal in 11% and 13% of pa-
tients, respectively. NT-pro-BNP levels were not related
to echocardiographic strain parameters, and troponin T
was a predictor of abnormal strain at 3 mo, but not at
1 y. These authors, therefore, concluded that the combi-
nation of cardiac biomarkers and 2-D STE is important
in the assessment of cardiac function of children treated
with anthracyclines.
Motoki et al. (2012) studied 25 patients (mean age:
58 6 11 y) before chemotherapy and 1 and 3 mo after
treatment. The cumulative anthracycline doses were 98
6 59 and 170 6 87 g/m2 at 1 and 3 mo, respectively.
LV dimensions and EF did not change throughout
follow-up, whereas significant deterioration in torsion,
twisting rate and untwisting rate was observed 1 mo after
chemotherapy. A significant negative correlation was
observed between cumulative anthracycline doses and
torsion (r 5 20.524, p , 0.0001).
Very recently, Florescu et al. (2014) reported on 40
women with breast cancer prospectively evaluated, as-
sessing both LV deformation (longitudinal, circumferen-
tial and radial strain and strain rate) and rotation after the
third and sixth cycles of epirubicin (mean cumulative
dose: 2686 22 g/m2). In the entire study population, after
the third cycle of epirubicin, there were reductions in
diastolic and longitudinal function. Although after the
third cycle of treatment radial and circumferential
deformation and rotation remained unchanged, these
parameters were significantly reduced after the sixth
cycle of epirubicin. Of note, a decrease in longitudinal
strain after the third cycle of epirubicin was the best
independent and accurate predictor of cardiotoxicity after
the completion of treatment.
Prediction of late cardiotoxicity development
The capability of early impairment of myocardial
systolic deformation to predict later development of
cardiotoxicity in patients with breast cancer treated
with anthracyclines and trastuzumab was been specif-
ically explored in two studies by Sawaya et al. In the first
study (Sawaya et al. 2011), these authors reported that the
decrease in GLS and increase in cardiac troponin plasma
concentration observed at 3 mo predict the development
of cardiotoxicity at 6 mo better than radial and circumfer-
ential strain. In particular, a 10% decrease in GLS had a
negative predictive value of 93%, whereas a 10%
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mo had a negative predictive value of 97%. Subsequent
cardiotoxicity was not clearly predicted by early changes
in the LV-EF or NT-proBNP level.
In a subsequent study in patients with early breast
cancer (Sawaya et al. 2012), a GLS value #219% after
anthracycline therapy was the only independent predictor
able to identify those patients developing LV systolic
dysfunction after additional trastuzumab treatment (12
mo after completion of anthracyclines). Although ultra-
sensitive troponin was not an independent predictor of
later cardiotoxicity, its measurement, combined with
the measurement of GLS, increased the negative predic-
tive value from 87% to 91%. Thus, measuring both strain
and troponin may be of value in predicting the lack of
toxicity of the cancer treatment.
Negishi et al. (2013) prospectively evaluated 81
consecutive women receiving trastuzumab, 37 of whom
received anthracyclines concurrently. Myocardial defor-
mation indices (GLS, GLSR-S, GLSR-E, as well as
GRS and GCS) were measured at baseline and at 6 and
12 mo. Among the three different components of LV
strain, only GLS, GLSR-S and GLSR-E were signifi-
cantly reduced in the cardiotoxicity group at 6 mo
compared with the group without cardiotoxicity, whereas
GRS and GCS were not. In the 24 patients (30%) who
later developed cardiotoxicity (defined as a .10%
decline as a percentage of baseline LV-EF in 12 mo),
GLS, GLSR-S and GLSR-E significantly decreased at 6
mo. The strongest predictor of cardiotoxicity was GLS
variation; an 11% reduction was the optimal cutoff,
with a sensitivity of 65% and specificity of 94%. The
addition of GLS to a model using clinical variables
(age, diabetes mellitus, hypertension, dyslipidemia and
smoking) and baseline LV-EF significantly improved
the power of the model for prediction of cardiotoxicity.
Mornos and Petrescu (2013) used a new index
combining LV longitudinal (by GLS) and torsional (by
LV twisting) deformations (GLS 3 LVtw) to evaluate
prospectively 74 patients treated for different types of
cancer before and after 6, 12, 24 and 52 wk of anthracy-
cline treatment. The receiver operating characteristic
curves identified early deterioration of GLS 3 LVtw as
the best predictor of later cardiotoxicity (area under
curve 5 0.93), followed by GLS (0.84) and LV apical
rotation (0.81) deterioration.
Evaluation of cardioprotection strategies
Few data are available on cardioprotection evaluated
by 2-D STE. Negishi et al. (2014) used this technique to
examine the response to cardioprotection with beta-
blockers in patients with breast cancer with subclinical
myocardial damage. They studied 159 patients receiving
anthracycline (n5 53), trastuzumab (n5 61) or trastuzu-mab after anthracyclines (n5 45). LV-EF and GLS were
measured at baseline and follow-up (7 6 7 mo). Patients
who decreased GLS by$11% were followed for another
6 mo. GLS improved in beta-blocker groups (from217.6
6 2.3% to219.86 2.6%, p, 0.001) but not in non-beta-
blocker groups (from 218.0 6 2.0% to 219.0 6 3.0%,
p 5 0.08). Effects of beta-blockers were similar with
all regimens. On the basis of these very preliminary
results, GLS seems to be an effective parameter for eval-
uation of response to cardioprotection in patients admin-
istered beta-blockers.Summary
According to the literature reported above on the use
of 2-D STE, it is evident that: impairment of myocardial
deformation is more sensitive than LV-EF reduction for
early recognition of asymptomatic LV systolic dysfunc-
tion caused by oncologic pharmacologic treatments; in
the setting of breast cancer treatment, a GLS reduction
after the first 3 mo of therapy predicts later development
of cardiotoxicity as defined by a reduction in LV-EF of at
least 10% (in particular, a decrease in GLS at the end of
the anthracycline treatment predicts late cardiotoxicity
after additional trastuzumb therapy); although radial
and circumferential deformation parameters decreased
significantly in many studies in patients treated with
oncologic drugs, longitudinal deformation indices seem
to be more sensitive than other parameters; there is only
limited experience with the use of rotational and torsional
indices in the clinical setting; studies are needed to
establish the role of 2-D STE in evaluation of response
to cardioprotection strategies, although preliminary
results seem to be very promising.
Intra- and inter-observer variability for strain and strain
rate measurements by 2-D STE is summarized in Table 2.3-D SPECKLE TRACKING
ECHOCARDIOGRAPHY
There are a few studies in the cardio-oncology field
on the use of 3-D-STE. Yu et al. (2013a) evaluated 53
anthracycline-treated survivors of childhood cancers
(mean age: 18.6 6 5.1 y) and 38 controls. Three-
dimensional STE was performed to assess LV 3-D
global and segmental strain, time-to-peak segmental
strain, LV torsion and EF. A LV systolic dyssynchrony
index (SDI) was calculated as the percentage of the
standard deviation of time-to-peak strain of 16 ventric-
ular segments divided by the length of one cardiac cycle
(i.e., the time between two R-waves). A global perfor-
mance index (GPI) was calculated as (global 3-D
strain 3 torsion)/SDI. Compared with controls, patients
had significantly reduced LV global 3-D strain (p ,
0.001), torsion (p , 0.001) and GPI (p , 0.001) and
Table 2. Intra- and inter-observer variability for strain and strain rate measurements by 2-D speckle tracking echocardiography
Reference
Number of
patients Age (y) Cancer Intra-observer variability Inter-observer variability
Ho et al. (2010) 70 54 6 8* Breast ICC (CV):
GLS: 0.97 (3.1%)
GRS: 0.97 (2.9%)
ICC (CV):
GLS: 0.95, (4.8%)
GRS: 0.97, (5.0%)
Tsai et al. (2011) 47 51 6 9 HL Cronbach a:
GLS: 0.98
Cronbach a:
GLS: 0.97
Cheung et al. (2011) 36 15.6 6 5.5 ALL Mean difference (SD):
LV torsion: 0.9 (5.0)
Peak systolic twisting velocity:
0.0/s (9.5/s)
Peak diastolic untwisting
velocity: 21.7/s (11.2/s)
Mean difference (SD):
LV torsion: 4.0 (7.1)
Peak systolic twisting
velocity: 22.1/s (10.8/s)
Peak diastolic untwisting
velocity: 22.0/s (14.4/s)
Stoodley et al. (2011a) 52 49 6 9 Breast Mean (SD):
GLS: 20.86 (0.59%)
GRS: 3.4 (12.4%)
GCS: 1.62 (1.10%)
Mean (SD):
GLS: 21.73 (1.0%)
GRS: 5.0 (7.8%)
GCS: 1.48 (1.24%)
Fallah-Rad et al. (2011) 42 47 6 9 Breast ICC (CV):
GLS: 0.94 (3.5%)
GRS: 0.91 (3.2%)
ICC (CV):
GLS: 0.90 (5.2%)
GRS: 0.82 (5.4%)
Sawaya et al. (2011) 43 49 6 10 Breast Mean error 6 SD—absolute
(relative) value:
LS: 20.14 6 1.1% (20.58 6 6.5%)
RS: 2 6 5% (2.5 6 9.6%)
CS: 0.53 6 2.82% (2 6 13%)
Mean error 6 SD—absolute
(relative) value:
LS: 0.5 6 1.5% (2.7 6 7.9%)
RS: 2.2 6 7.5% (4.4 6 14.4%)
CS: 3.3 6 3.5% (19 6 21%)
Motoki et al. (2012) 25 58 6 11 NHL, ALL,
AML
Mean difference (LsA)
LV torsion: 20.21 (1.18, 21.60)
Mean difference (LsA)
LV torsion: 20.26 (1.33, 21.85)
Poterucha et al. (2012) 19 15.3 6 3 Various Mean difference (LsA), CV:
GLS: 0.0 (3.32, 23.32), 10%
Mean difference (LsA), CV:
GLS: 0.29 (2.87, 22.28), 7.2%
Yu et al. (2013b) 32 19.3 6 5.4 Various CV:
GLS IL: 3.32%, OL: 2.68%
GRS IL: 2.72%, OL: 5.38%
GCS IL: 3.18%, OL: 3.39%
Ap rotation IL: 2.49%, OL: 4.66%
Ap twisting velocity IL: 2.56%,
OL: 6.29%
Ap untwisting velocity IL: 3.60%,
OL: 5.19%
CV:
GLS IL: 10.32%, OL: 7.70%
GRS IL: 2.86%, OL: 5.50%
GCS IL: 3.34%, OL: 6.88%
Ap rotation IL: 6.71%, OL: 7.92%
Ap twisting velocity IL: 7.16%,
OL: 10.07%
Ap untwisting velocity IL: 8.51%,
OL: 13.35%
Mornos and
Petrescu (2013)
74, 37 controls 51 6 11 Various ICC (CV):
GLS: 0.95 (2.6%)
GRS: 0.91 (2.9%)
ICC:
GLS: 0.91 (3.9%)
GRS: 0.84 (5.1%)
Kang et al. (2013) 67 52.5 6 13.8 NHL ICC:
GLS: 0.89
GCS: 0.98
GRS: 0.94
ICC:
GLS: 0.85
GCS: 0.82
GRS: 0.89
Stoodley et al. (2013b) 52 49 6 9 Breast Mean difference (LsA):
GLS: 20.86 (0.3, 22.02)
GRS: 3.4 (27.7, 220.9)
GCS: 1.62 (3.78, 20.54)
Mean difference (LsA):
GLS: 21.73 (0.23, 23.69)
GRS: 5 (20.3, 210.3)
GCS: 1.48 (3.9, 20.92)
Stoodley et al. (2013a) 78 52 6 10 Breast CV:
GLS: 9.9%
CV:
GLS: 9.0%
Khouri et al. (2014) 57 51 6 10 Breast ICC (95% CI):
GLS: 0.97 (0.9220.99)
No data
Florescu et al. (2014) 40 51 6 8 Breast CV:
RS: 610.1%
RSR: 68.8%
CS: 67.6%
CSR: 69.9%
LS: 63.3%
LSR: 62.9%
Twisting: 620.5%
Untwisting rate: 6 18.4%
CV:
RS: 615.1%
RSR: 610.7%
CS: 64.2%
CSR: 67.6%
LS: 64.2%
LSR: 62.9%
Twisting: 618.1%
Untwisting rate: 615.1%
ALL5 acute lymphoblastic leukemia;AML5 acutemyeloid leukemia;Ap5 apical;CI5 confidence interval;CS5 circumferential strain;CSR5 circum-
ferential strain rate; CV 5 coefficient of variation; GLS 5 global longitudinal strain; GLSR 5 global longitudinal strain rate; GRS 5 global radial strain;
GRSR 5 global radial strain rate; HL 5 Hodgkin’s lymphoma; ICC 5 intra-class correlation coefficient; IL 5 inner layer; LS 5 longitudinal strain;
LsA5 limits of agreement; LSR 5 longitudinal strain rate; NHL5 non-Hodgkin’s lymphoma; OL5 outer layer; RS5 radial strain; RSR 5 radial strain
rate; SD5 standard deviation; SR5 strain rate.
* Mean 6 SD.
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Table 3. Intra- and inter-observer variability for strain and strain rate measurements by 3-D speckle tracking echocardiography
Reference Number of patients Age (y) Cancer Intra-observer variability Inter-observer variability
Yu et al. (2013a) 53 18.6 6 5.1 Various Coefficient of variation:
Global 3-D strain: 7.3%
Twist: 7.5%
Torsion: 7.7%
Coefficient of variation:
Global 3-D strain: 8.2%
Twist: 10.3%
Torsion: 10.7%
Miyoshi et al. (2014) 50 1 20 controls 54 6 15 Various ICC (95% confidence interval):
3-D-GRS: 0.946 (0.87020.979)
3-D-GCS: 0.943 (0.86220.977)
3-D-GLS: 0.908 (0.78220.963)
3-D-GAS: 0.923 (0.81620.969)
ICC (95% confidence interval):
3-D-GRS: 0.906 (0.66820.976)
3-D-GCS: 0.887 (0.67220.964)
3-D-GLS: 0.891 (0.68320.966)
3-D-GAS: 0.849 (0.57820.951)
CV5 coefficient of variation; GAS5 global area strain; GCS5 global circumferential strain; GLS5 global longitudinal strain; ICC5 intra-class
correlation coefficient. *Mean 6 SD.
640 Ultrasound in Medicine and Biology Volume 41, Number 3, 2015greater SDI (p, 0.001). A GPI cutoff of 10.6/cm had a
sensitivity of 84.9% and a specificity of 81.6% in
differentiating patients from controls. The advantage
of the LV GPI obtained by 3-D-STE is that it incorpo-
rates LV 3-D strain, dyssynchrony and torsion for the
sensitive detection of altered LV mechanics in child-
hood cancer survivors. Although this approach merits
further validation, at present it appears to be relatively
complex and difficult to implement in routine clinical
practice.
Miyoshi et al. (2014) studied 50 patients with pre-
served LV-EF (all $55%) after receiving anthracycline
chemotherapy and 20 matched normal volunteers. With
3-D-STE, 3-D radial, circumferential and longitudinal
myocardial functionwas quantified as a peak global strain
curve from 16 LV segments; also, LV endocardial area
change ratio (area strain) was quantified as peak global
area strain curve (3-D-GAS) to determine LVendocardial
function. Only 3-D-GAS and peak 3-D global circumfer-
ential strains of the anthracycline group were signifi-
cantly worse than those of the control group (243.3 6
3.1% vs. 245.8 6 4.3%, p 5 0.008, and 231.6 6 3.5%
vs. 234.4 6 4.2%, p 5 0.004, respectively), whereas
global LV systolic function and diastolic function were
similar. It was noteworthy that multivariate analysis
revealed that only 3-D-GAS (p 5 0.025) was indepen-
dently associated with cumulative doxorubicin dose.
The authors concluded that 3-D-STE area strain is useful
for early detection of minor LV endocardial dysfunction
associated with the use of anthracyclines. However,
whether this approach is clinically useful for predicting
global LV dysfunction remains to be demonstrated.
Intra- and inter-observer variability for strain and
strain rate measurements by 3-D-STE is reported in
Table 3.VELOCITY VECTOR IMAGING
Only few data are available on the evaluation of
cardiotoxicity with VVI. Park et al. (2009) reported, in asmall group 14 asymptomatic patients who had been
treatedwith anthracyclines and had normal LV-EF, that an-
thracycline therapy, even at a low dose (,300 mg/m2),
can induce changes in the regional peak systolic strain
and strain rate obtained with VVI (especially at the septal
level) before global dysfunction. These authors also calcu-
lated the intra-observer variability, as the mean difference
[95% confidence interval], for peak systolic strain (0.99%
[22.32, 1.76]), peak systolic strain rate (0.13/s [20.29,
0.24]) and diastolic strain rate (0.18/s [20.40, 0.32]).
Moon et al. (2014) using VVI retrospectively
analyzed the echocardiograms of 71 pediatric cancer
patients with normal LV shortening fraction before
anthracycline exposure and after completion of treat-
ment. After anthracycline exposure (time from diagnosis
to follow-up5 3.96 4.0 y), pediatric cancer patients had
lower longitudinal and circumferential systolic and
diastolic strain and strain rate values compared with
controls. Diastolic strain rate exhibited the greatest
percentage difference after anthracycline exposure versus
controls. Whether the decline in strain or strain rate
obtained with VVI can predict future risk of developing
cardiomyopathy requires further investigation.INSIGHTS FROM HISTOLOGIC FINDINGS
During anthracycline treatment, histologic signs of
damage can be detected in myocardial biopsies, even at
low doses when no clinical signs of heart failure are
present (Billingham et al. 1978; Mason et al. 1978).
This is in agreement with the echocardiographic
findings (Bi et al. 2009; Cadeddu et al. 2010; Mercuro
et al. 2007; Park et al. 2009; Zhang et al. 2012). The
damage is more prominent in the left ventricle and
especially in the subendocardial layer of the myocardial
walls (Mortensen et al. 1986), as also reported in other
cardiac diseases ranging from the ischemic heart disease
to hypertension and diabetes. It has been speculated that
a reduced redox potential in the subendocardial region
makes it more susceptible to oxidative stress and could
Echocardiography and cardiotoxicity d D. MELE et al. 641contribute to the final damage. Because the suben-
docardium comprises mainly longitudinal myocardial
fibers (Greenbaum et al. 1981), it appears reasonable
that early damage caused by anthracycline therapy may
result in deterioration of longitudinal cardiac function.
This may also explain why some authors have identified
longitudinal myocardial strain as a better parameter than
radial and circumferential myocardial deformation for
recognition of chemotherapy-induced cardiotoxicity
(Sawaya et al. 2011).CLINICAL IMPLICATIONS
The vast majority of the currently available studies
indicate that ultrasound deformation imaging is more
sensitive than LV-EF in detecting early impairment of
LV systolic function caused by oncologic treatments
(both chemo- and radiotherapy). This observation is inde-
pendent of the specific ultrasound technique used in
different studies (DSI, 2-D- or 3-D-STE, VVI). Addition-
ally, by the use of ultrasound deformation imaging,
chemotherapy-induced cardiotoxicity has been repeat-
edly recognized at low doses of anthracyclines and before
or in the absence of development of diastolic dysfunction.
In general, assessment of longitudinal myocardial
strain, and specifically systolic GLS by 2-D-STE, has
provided more consistent results than radial and circum-
ferential myocardial deformation analysis. Systolic GLS
has also been found to be relatively easy to obtain and
reproducible. Therefore, this parameter seems suitable
for application in the clinical setting. The DSI technique
can be proposed only as a second choice.
In patients with early breast cancer at risk for
trastuzumab-induced cardiotoxicity, GLS may be used
as an independent and incremental early predictor of later
reduction in LV-EF. In particular, a relative GLS decrease
of .10% compared with baseline is very likely to be
abnormal. In patients without baseline strain measure-
ments, a cutoff of219% might be used, although change
in strain appears to be preferable. Further studies, howev-
er, are needed to clarify the relative contributions of
different GLS criteria in predicting late cardiotoxicity.
Encouraging results have been published on the role
of deformation imaging for assessment of cardioprotec-
tion strategies, but studies are scarce. This is, therefore,
a promising field for future research and especially for
multicenter trials.
At present there are no guidelines for cardiotoxicity
definition other than the CREC (Seidman et al. 2002) and
ESMO (Bovelli et al. 2010) criteria based on LV-EF.
However, on the basis of the results discussed above,
we believe that use of LV strain analysis, where available,
should be encouraged for assessment of myocardial
function during oncologic treatments, in addition toconventional systolic and diastolic evaluations. In partic-
ular, patients who have a significant reduction in systolic
GLS after chemo- or radiotherapy in the absence of
significant LV-EF variations could be proposed for
more frequent echocardiographic evaluations, additional
imaging studies (e.g., cardiac MRI to verify the myocar-
dial substrate of LV dysfunction) or pharmacologic cardi-
oprotection strategies.
Studies on large patient populations are needed to
bring use of deformation imaging into extensive routine
clinical practice for the detection and prevention of
cardiotoxicity.REFERENCES
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